The University of Chicago Comprehensive Cancer Center (UCCCC) is led by a Strong Leadership Team, which effectively represents all components of the academic units Involved In cancer research and clinical care, and tightly links the basic, clinical, translational and population research programs. The Senior Leaders includes 2 Co-Deputy Directors and 7 Associate Directors. Over the past 5 years, strategic changes In the leadership have facilitated the development of an Integrated and shared vision for the cancer programs. New appointments, together with considerable continuity of leadership, have enhanced organizational and planning capabilities. Richard Schilsky, MD (Chief, Section of Hematology/ Oncology) replaced Dr. Vokes (who was appointed Chair of Medicine) as Co-Deputy Director for Clinical Sciences. He works closely with Marsha Rosner, PhD (Chair, Ben May Department for Cancer Research) who remains as the Co-Deputy Director for Basic Sciences. The Associate Directors for Basic Sciences (Geoffrey Greene, PhD, Vice Chair of the Ben May Department for Cancer Research), Clinical Sciences (Mark Ratain, MD, Professor of Medicine, Director, Center for Personalized Therapeutics), and Population Research (Habibul Ahsan, MBBS, MMedSc, Professor of Health Studies, Director, Center for Cancer EpWemiology and Prevention), all recognized as leaders in their fields, continue in their roles. Marcy List, PhD, continues in her role as Associate Director for Administration. James Schilling, PhD, an experienced investigator with expertise in proteomics, now serves as the Associate Director for Core Facilities, and Executive Director of the BSD Office of Shared Research Facilities. In 2011, the UCCCC created two new positions, the Associate Director for Translational Sciences (Ravi Salgia, MD, PhD, Professor of Medicine, Vice Chair for Translational Research, Dept. of Medicine) and the Associate Director for Education (Ezra Cohen, MD, Associate Professor of Medicine, Director of the Hematology/Oncology Fellowship Program). The above individuals are members (with the exception of the Associate Director for Core Facilities) of the UCCCC Executive Committee (EC) and the Cancer Advisory Committee (CAC). The CAC also includes additional leaders of academic units engaged In cancer research and care of patients with cancer, e.g.. Radiation Oncology, Surgical Oncology, Urology and Pediatric Hematology/Oncology. The Deputy Directors and Associate Directors, work closely with the Director, and are responsible for strategic planning, general administration of the UCCCC and Implementation of specific programs within their areas. Together they are responsible for identifying and implementing interdisciplinary efforts, identifying recruitment needs, leading recruitment searches, prioritizing allocation of UCCCC resources (including final decisions about the Pilot Project awards), developing new shared resources, and worthing with the Program Leaders In advancing programmatic goals. Over the past year, this group has taken primary responsibility for developing the UCCCC Strategic Plan.

Public Health Relevance

Advancing the UCCCC's mission, to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer, requires a strategic vision and an emphasis on translational and interdisciplinary research The Senior Leadership Team is responsible for developing this vision, and creating the environment and Infrastructure necessary for collaboration among a diverse and dedicated team of outstanding basic, clinical, translational, and population researchers, and trainees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-39
Application #
8744845
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$189,036
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977

Showing the most recent 10 out of 668 publications